Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Cost of RevenueEBIATGross ProfitLeasesLong-Term Debt IssuancesOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsReceivables - NetShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Tg Therapeutics (TGTX) Cost of Revenue (2021 - 2025)

Tg Therapeutics has reported Cost of Revenue over the past 5 years, most recently at $38.1 million for Q4 2025.

  • Quarterly results put Cost of Revenue at $38.1 million for Q4 2025, up 147.69% from a year ago — trailing twelve months through Dec 2025 was $100.7 million (up 161.7% YoY), and the annual figure for FY2025 was $100.7 million, up 161.69%.
  • Cost of Revenue for Q4 2025 was $38.1 million at Tg Therapeutics, up from $28.1 million in the prior quarter.
  • Over the last five years, Cost of Revenue for TGTX hit a ceiling of $38.1 million in Q4 2025 and a floor of $2000.0 in Q3 2022.
  • Median Cost of Revenue over the past 5 years was $7.9 million (2023), compared with a mean of $10.2 million.
  • Biggest five-year swings in Cost of Revenue: skyrocketed 261700.0% in 2023 and later skyrocketed 96.07% in 2024.
  • Tg Therapeutics' Cost of Revenue stood at $139000.0 in 2021, then plummeted by 97.84% to $3000.0 in 2022, then skyrocketed by 261700.0% to $7.9 million in 2023, then skyrocketed by 96.07% to $15.4 million in 2024, then skyrocketed by 147.69% to $38.1 million in 2025.
  • The last three reported values for Cost of Revenue were $38.1 million (Q4 2025), $28.1 million (Q3 2025), and $18.9 million (Q2 2025) per Business Quant data.